title: Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.
abstract: BACKGROUND
  A 39-year-old woman with no relevant medical or family history was admitted to hospital with episodic fever, which persisted despite antibiotic therapy. Other notable findings at admission were splenomegaly, pancytopenia, hyponatremia, elevated levels of liver enzymes, hyperferritinemia and hypofibrinogenemia.
  
  
  METHODS
  Physical examination, laboratory tests, rheumatic marker serology, pathogen detection assays, complete blood counts, measurement of levels of ferritin, fibrinogen, triglycerides and soluble CD25, natural killer cell functional studies, PRF1 mutation analysis, renal biopsy, bone marrow biopsy, CT imaging of the chest and abdomen.
  
  
  METHODS
  Idiopathic, atypical hemophagocytic lymphohistiocytosis.
  
  
  RESULTS
  Initial treatment with antibiotics was followed by immunosuppressive therapy (including intravenous immunoglobulin, ciclosporin, infliximab, corticosteroids and etoposide). Remission was achieved by treatment with the anti-CD52 monoclonal antibody, alemtuzumab, after which allogeneic stem-cell transplantation (with reduced-intensity conditioning treatment and graft-versus-host disease prophylaxis) resulted in a definitive cure.
authors.affiliation: Section of Hematology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA. matthew.strout@yale.edu
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Strout
authors.forename: Stuart
authors.initials: S
authors.lastname: Seropian
authors.forename: Nancy
authors.initials: N
authors.lastname: Berliner
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis / Q000628:therapy*; D012074:Remission Induction; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab
references.citation: Cell. 2003 Nov 14;115(4):461-73
references.pmid: 14622600
references.citation: Curr Opin Hematol. 2008 Jul;15(4):359-67
references.pmid: 18536575
references.citation: Hum Mutat. 2006 Jan;27(1):62-8
references.pmid: 16278825
references.citation: Pediatr Blood Cancer. 2007 Feb;48(2):124-31
references.pmid: 16937360
references.citation: Blood. 2002 Oct 1;100(7):2367-73
references.pmid: 12239144
references.citation: Immunology. 2009 Oct;128(2):260-70
references.pmid: 19740383
references.citation: Eur J Pediatr. 2007 Feb;166(2):95-109
references.pmid: 17151879
references.citation: Science. 1999 Dec 3;286(5446):1957-9
references.pmid: 10583959
references.citation: Ann Hematol. 2007 Nov;86(11):847-9
references.pmid: 17579863
references.citation: Oncogene. 2007 May 28;26(25):3644-53
references.pmid: 17530018
references.citation: Med Pediatr Oncol. 1997 May;28(5):342-7
references.pmid: 9121398
references.citation: Pediatr Blood Cancer. 2008 Feb;50(2):419-21
references.pmid: 16900487
references.citation: Br J Haematol. 2005 Jun;129(5):622-30
references.pmid: 15916685
references.citation: J Exp Med. 1980 May 1;151(5):1039-48
references.pmid: 6154765
references.citation: Pediatrics. 2007 Sep;120(3):e622-8
references.pmid: 17698967
references.citation: Bone Marrow Transplant. 2006 Apr;37(8):797-8
references.pmid: 16518425
references.citation: Hematology Am Soc Hematol Educ Program. 2009;:127-31
references.pmid: 20008190
references.citation: Br J Haematol. 2000 Mar;108(4):834-7
references.pmid: 10792291
references.citation: Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S47-50
references.pmid: 18978744